SLC7A11 and nasopharyngeal carcinoma: Thus, the study investigated the potential therapeutic effects of sorafenib, a multi-target tyrosine kinase inhibitor, in NPC, focusing on its ability to target SLC7A11 and its impact on T-cell recognition and cytotoxicity.